密钙息防治闭经患者骨丢失机制的探讨

Effect of calcitonin on bone loss in patients with amenorrhea

本文作者对20例高促性腺激素性闭经患者给予密钙息用药3个月,并于给药前后分别测定空腹尿钙与肌酐(Ca/Cr)、羟脯氨酸与肌酐(OHPr/Cr)比值以及血清雌二醇(E2)、降钙素(CT)和碱性磷酸酶(AKP)的值,以了解上述年轻但已有显著雌激素缺乏的患者其骨代谢对密钙息用药的反应性,结果发现,密钙息给药前后患者之血清AKP及E2的水平差异未见显著性,但其空腹尿Ca/Cr、OH-Pr/Cr比值却均较给药前显著下降(P<0.05或P<0.01)。血清CT的水平较给药前有升高趋势,说明密钙息可抑制高促性腺激素性闭经患者骨质的吸收,促进其骨质的形成,故此密钙息对防治闭经患者骨质疏松的发生有重要的临床意义。

In order to understand the bone metabolic reaction to calcitonin for patients with hypoestrinemi-a. Primary amenorrhea were treated with calcitonin for three months. Then fasting urinary calcium creatinine ratio ( Ca/Cr) , hydroxyproline creatinine ratio(OHPr/Cr)、serum alkaline phosphatase( AKP)、estradiol(E2)、calcitonin (CT) were determined for theses patients before and afte treatment. The results showed that AKP and E2 values were not significantly altered, but Ca/Cr and OHPr/Cr were lowered (P < 0.05 or P < 0.01) in these patients with calcitonin after treatment. The level of CT increased (P > 0.05) after treatment. It is conclude that the ad-ministration of calcitonin is of clinical significance for prevention of osteoporosis in hypergonadotropic amenorrhea patients.